| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
IC50: 30 nM (PACAP type I receptor), 600 nM (PACAP type II receptor VIP1), 40 nM (PACAP type II receptor VIP2)[1]
|
|---|---|
| ln Vitro |
It is also possible to detect a rise in dopamine (DA) content by HPLC analysis and/or cell proliferation detected by the MTT assay by Dexamethasone (DEX). These effects can be prevented by PACAP (6-38) at concentrations high enough to block the PACAP type 1 (PAC1) receptor. This rise in DA content by 1 μM DEX is strongly inhibited by pretreatment with PAC1 receptor antagonist PACAP(6-38) at 0.1 or 1 μM for 2 hours. DEX promotes cell growth, as demonstrated by the MTT experiment. Furthermore, PACAP's pre-incubation inhibits this effect as well (6-38). DA content and cell proliferation are unaffected by PACAP(6-38) at 1μM for a 24-hour period. It has been reported, meanwhile, that PACAP(6-38) at 0.3 μM can inhibit the spontaneous buildup of tyrosine hydroxylase (TH) in differentiated retinal cultured cells over a period of five days[2].
|
| ln Vivo |
In NGF-OE mice, intravesical injection of PACAP (6-38), a PAC1 receptor antagonist, significantly increases both the void volume (2.5-fold) and intercontraction interval (2.0-fold). NGF-OE mice's baseline bladder pressure is likewise reduced by intravesical administration of PACAP (6-38). While PACAP (6-38) (300 nM) administered intravenously considerably (p≤0.01) lowers pelvic sensitivity in NGF-OE mice, it has no impact in WT animals[3].
|
| References |
|
| Molecular Formula |
C184H301N56FO47S
|
|---|---|
| Molecular Weight |
4138.76
|
| Related CAS # |
PACAP (6-38), human, ovine, rat;143748-18-9
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~24.16 mM)
H2O :~50 mg/mL (~12.08 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 100 mg/mL (24.16 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2416 mL | 1.2081 mL | 2.4162 mL | |
| 5 mM | 0.0483 mL | 0.2416 mL | 0.4832 mL | |
| 10 mM | 0.0242 mL | 0.1208 mL | 0.2416 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
